Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-Hepatobiliary
jRCT2031230260Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Open-label trial of volrustomig, rilvegostomig, bevacizumab, lenvatinib, gemcitabine and 1 more in hepatocellular carcinoma (HCC) and biliary cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate, Adverse events and serious adverse events and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
volrustomigrilvegostomigbevacizumablenvatinibgemcitabine
03
Conditions
hepatocellular carcinoma (HCC)biliary cancer
Beyond the preview
Go deeper on jRCT2031230260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230260.